Research has demonstrated that the phosphoinositide 3 kinase (PI3K) and Mitogen-Activated Protein Kinase (MAPK) signaling pathways play an important role in mediating resistance to doxorubicin in cancer cells54–57. The gene discussed is WNK2; the disease is cancer.